Are we nearly there yet? Starts and stops on the road to use of polygenic scores

Sowmiya Moorthie^{1

2}, Daphne Oluwasen Martschenko³, Segun Fatumo^{4

5}

Affiliations

¹ PHG Foundation, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. sowmiya.moorthie@phgfoundation.org.
² Cambridge Public Health, University of Cambridge School of Clinical Medicine, Forvie Site, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0SR. sowmiya.moorthie@phgfoundation.org.
³ Department of Pediatrics, Stanford Medicine, Center for Biomedical Ethics, Stanford University, Stanford, CA, USA.
⁴ The African Computational Genomic (TACG) Research Group, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Editorial

Sowmiya Moorthie et al. J Community Genet. 2023 Oct.

. 2023 Oct;14(5):439-440.

doi: 10.1007/s12687-023-00672-w.

Sowmiya Moorthie^{1

2}, Daphne Oluwasen Martschenko³, Segun Fatumo^{4

5}

¹ PHG Foundation, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. sowmiya.moorthie@phgfoundation.org.
² Cambridge Public Health, University of Cambridge School of Clinical Medicine, Forvie Site, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0SR. sowmiya.moorthie@phgfoundation.org.
³ Department of Pediatrics, Stanford Medicine, Center for Biomedical Ethics, Stanford University, Stanford, CA, USA.
⁴ The African Computational Genomic (TACG) Research Group, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

No abstract available

Cited by

The impact of supplementing traditional risk information with polygenic risk score concerning type 2 diabetes and coronary heart disease on health behavior: a randomized controlled trial.
Halmesvaara O, Lonna M, Kääriäinen H, Perola M, Kristiansson K, Konttinen H. Halmesvaara O, et al. J Community Genet. 2025 Jun;16(3):373-386. doi: 10.1007/s12687-025-00790-7. Epub 2025 Mar 26. J Community Genet. 2025. PMID: 40140145 Free PMC article.
Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients' Perspectives on Influencing Factors and Strategies.
Purvis R, Taylor N, James P, Young MA, Forrest LE. Purvis R, et al. Patient. 2025 Jun 28. doi: 10.1007/s40271-025-00747-5. Online ahead of print. Patient. 2025. PMID: 40580369
Readiness and leadership for the implementation of polygenic risk scores: Genetic healthcare providers' perspectives in the hereditary cancer context.
Purvis R, Taylor N, Young MA, James P, Forrest LE. Purvis R, et al. J Genet Couns. 2025 Aug;34(4):e70084. doi: 10.1002/jgc4.70084. J Genet Couns. 2025. PMID: 40692272 Free PMC article.

1. ACMG Board of Directors ’Direct-to-consumer prenatal testing for multigenic or polygenic disorders: a position statement of the American College of Medical Genetics and Genomics (ACMG)’. Genet Med. 2021;23(11):2027–2028. doi: 10.1038/s41436-021-01247-1. - DOI - PubMed
1. Chapman CR (2022) Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores. J Community Genet. 10.1007/s12687-022-00625-9 - PMC - PubMed
1. Cornel MC, van El CG, Borry P. The challenge of implementing genetic tests with clinical utility while avoiding unsound applications. J Community Genet. 2014;5(1):7–12. doi: 10.1007/s12687-012-0121-1. - DOI - PMC - PubMed
1. Fatumo S, Chikowore T, Choudhury A, Ayub M, Martin AR, Kuchenbaecker K. A roadmap to increase diversity in genomic studies. Nat Med. 2022;28(2):243–250. doi: 10.1038/s41591-021-01672-4. - DOI - PMC - PubMed
1. Johnston J, Matthews LJ. Polygenic embryo testing: understated ethics, unclear utility. Nat Med. 2022;28(3):446–448. doi: 10.1038/s41591-022-01743-0. - DOI - PMC - PubMed